偷吃步解法：(1), (4) 必選，選(E)

(1) ✓ 正確。BRCA1/2胚細胞系突變確實會顯著增加女性罹患乳癌和卵巢癌的風險。BRCA1突變者一生中罹患乳癌的風險約為65-80%，卵巢癌風險約為39-44%；BRCA2突變者乳癌風險約為45-69%，卵巢癌風險約為11-17%。

Kurian AW, Gong GD, John EM, et al. Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: Findings From the Breast Cancer Family Registry - PMC. Journal of Clinical Oncology. 29(34). doi:10.1200/JCO.2010.34.4440
  
(2) ✓ 正確。2002 NEJM發表：預防性卵巢切除術(prophylactic oophorectomy)不僅可降低卵巢癌風險，研究也顯示它可減少BRCA突變帶因者乳癌風險約50%，主要是通過降低雌激素水平的機制。

Rebbeck TR. Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations. The New England Journal of Medicine. May 23, 2002. Accessed March 6, 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa012158

(3) ✓ 正確，PARP抑制劑在BRCA突變的轉移性乳癌患者中提高了無疾病惡化存活期(PFS)，當年尚未證實它們在整體存活期(OS)方面有顯著優勢，但近期 OlympiAD 在2024發表中，在線使用有OS benifit，故正確。

Robson ME, Im SA, Senkus E, et al. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. European Journal of Cancer. 2023;184:39-47. doi:10.1016/j.ejca.2023.01.031
  
Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523-533.

Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med.
2018;379(8):753-763.

(4) ✓ 正確。BRCA突變的腫瘤存在DNA修復缺陷，對引起DNA損傷的藥物特別敏感。Cells with BRCA1 pathogenic variant are more sensitive to platinum-based chemotherapeutic agents, which disrupt the DNA structure。

3.Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D. The effect of loss of BRCA1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol. 2003;22:1169–1173.

4.Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 2003;88:1285–1291. doi: 10.1038/sj.bjc.6600859IF: 6.4 Q1 .